Results 271 to 280 of about 386,415 (318)

Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis. [PDF]

J Respir Biol Transl Med
Zhao T, Su Y.
europepmc   +1 more source

Atopic children with cystic fibrosis have increased urinary leukotriene E concentrations and more severe pulmonary disease

, 1994
Peter Greally, Angus Cook, Anthony P. Sampson, Robert E. Coleman, Suzanne K. Chambers, Piper Pj, Jack Price   +6 more
openalex   +1 more source

Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling [PDF]

, 2017
Chen, Lin, Dorry, Samuel J, Guzy, Robert D, Koo, Hyun Young, Li, Ling, Ornitz, David M, Smith, Craig   +6 more
core   +2 more sources

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings

ESC Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome accounting for half of heart failure cases. Although natriuretic peptides are the most accepted and extensively used biomarkers for heart failure, their diagnostic accuracy for HFpEF remains debatable.
Reza Parvan, Natale Rolim, Andreas B. Gevaert, Alessandro Cataliotti, Emeline M. van Craenenbroeck, Volker Adams, Ulrik Wisløff, Gustavo Jose Justo Silva, on behalf of the OptimEx Study Group   +8 more
wiley   +1 more source

Characterizing the Emergence of Myeloid-Derived Suppressor Cell Subsets in a Murine Model of Pulmonary Fibrosis. [PDF]

FASEB J
Vedder N, Gercke P, Lautenschlager N, Brunn T, Lange T, Schieb J, Vetter C, van Geffen C, Kolahian S.   +8 more
europepmc   +1 more source

Current and novel biomarkers in cardiogenic shock

European Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog   +5 more
wiley   +1 more source

SIRT3/6/7: promising therapeutic targets for pulmonary fibrosis. [PDF]

Front Cell Dev Biol
Huang P, Qin D, Qin Y, Tao S, Liu G.
europepmc   +1 more source

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high‐, middle‐ and low‐income countries – A Global Congestive Heart Failure (G‐CHF) study

European Journal of Heart Failure, EarlyView.
Abstract Aims The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure (HF) from countries of different income levels. Methods and results We enrolled 17 321 participants with HF from 40 countries.
Darryl P. Leong, Philip G. Joseph, Hisham Dokainish, Stefan Störk, John V.V. McMurray, Lisa M. Mielniczuk, Sanjib Kumar Sharma, Andrés Orlandini, Kamilu M. Karaye, Antoni Bayes‐Genis, Tara McCready, Alex Grinvalds, Kumar Balasubramanian, Kelley R. Branch, Kristian Kragholm, Salim Yusuf, on behalf of the G‐CHF Investigators   +16 more
wiley   +1 more source

Identification of genetic indicators linked to immunological infiltration in idiopathic pulmonary fibrosis. [PDF]

Medicine (Baltimore)
Huang Y, Ouyang Y, Luo W, Huang S.
europepmc   +1 more source